已收盤 10-10 16:00:00 美东时间
-1.980
-5.51%
今日重点评级关注:HC Wainwright & Co.:维持Inventiva"买入"评级,目标价从20美元升至24美元;摩根大通:维持BioMarin Pharmaceutical"超配"评级,目标价从116美元升至119美元
10-10 11:36
Scotiabank analyst Paul Cheng maintains CVR Energy (NYSE:CVI) with a Sector Underperform and raises the price target from $25 to $26.
10-09 22:36
今日重点评级关注:Benchmark:维持Unicycive Therapeutics"投机性买入"评级,目标价从3美元升至21美元;Guggenheim:维持Amylyx Pharmaceuticals"买入"评级,目标价从17美元升至25美元
09-16 09:48
Top Wall Street analysts changed their outlook on these top names. For a comple...
09-15 19:15
Mizuho analyst Nitin Kumar downgrades CVR Energy (NYSE:CVI) from Neutral to Underperform and raises the price target from $27 to $29.
09-15 19:07
CVR Energy ( ($CVI) ) has provided an update. On September 2, 2025, CVR Energy,...
09-03 04:54
An announcement from CVR Energy ( ($CVI) ) is now available. On August 22, 2025...
08-29 20:24
An update from ZF Commercial Vehicle Control Systems India Limited ( ($IN:ZFCVI...
08-26 13:35
enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received a not-approvable letter from
08-20 19:09